1981
Animal toxicology for early clinical trials with anticancer agents.
Rozencweig M, Von Hoff D, Staquet M, Schein P, Penta J, Goldin A, Muggia F, Freireich E, DeVita V. Animal toxicology for early clinical trials with anticancer agents. American Journal Of Clinical Oncology 1981, 4: 21-8. PMID: 6783332.Peer-Reviewed Original ResearchConceptsPhase I clinical trialEarly clinical trialsClinical trialsOrgan system toxicityStarting doseSystem toxicityChemotherapeutic agentsDose-escalation stepsCommon toxic effectsGastrointestinal intoleranceInitial doseClinical dataEscalation stepsAnimal findingsToxic doseToxic manifestationsIndividual drugsPredictive valueAnimal toxicologyMiceDoseIdentical scheduleLD10Acceptable dosesDogs
1970
The physiological disposition of the carcinostatic imidazole-4 (or 5)-carboxamide, 5(or 4)-[3,3-bis(2-chloroethyl)-1-triazeno] (NSC 82196) (imidazole mustard) in mice and dogs.
Vogel C, Denham C, Waalkes T, DeVita V. The physiological disposition of the carcinostatic imidazole-4 (or 5)-carboxamide, 5(or 4)-[3,3-bis(2-chloroethyl)-1-triazeno] (NSC 82196) (imidazole mustard) in mice and dogs. Cancer Research 1970, 30: 1651-7. PMID: 5457935.Peer-Reviewed Original ResearchConceptsPhysiological disposition
1967
The physiological disposition of the carcinostatic 1,3‐bis(2‐chloroethyU‐l‐nitrosourea (BCNU) in man and animals
DeVita V, Denham C, Davidson J, Oliverio V. The physiological disposition of the carcinostatic 1,3‐bis(2‐chloroethyU‐l‐nitrosourea (BCNU) in man and animals. Clinical Pharmacology & Therapeutics 1967, 8: 566-577. PMID: 4951973, DOI: 10.1002/cpt196784566.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCarmustineDogsFemaleHumansMacaca mulattaMaleMiceMice, Inbred StrainsSpecies Specificity